Skip to main content

SYMBRAVO

Generic: meloxicam, rizatriptan

Verified·Oct 26, 2026
NDC
81968-020
RxCUI
2711789
Route
ORAL
ICD-10 indication
G43.909

Affordability Check

How much will you actually pay for SYMBRAVO?

In 30 seconds, see every legitimate way to afford SYMBRAVO — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About SYMBRAVO

This record is invalid as the drug name does not exist; potential intended medications include Simbrinza (brinzolamide/brimonidine) or Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide).

Copay & patient assistance

  • Patient Copay Amount: As little as $0
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Must have commercial (private) insurance; not valid for patients with insurance through federal or state healthcare programs (e.g., Medicare, Medicaid, TRICARE); not valid for cash-paying patients; must be a resident of the United States or U.S. territories; patient or guardian must be 18 years of age or older.
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.